Compare Duke Energy Corp (DUK) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs Sanofi SA — how do they compare? Duke Energy Corp trades at $116.58 (market cap $91.10B), while Sanofi SA trades at $40 (market cap $95.18B). The key difference: Duke Energy Corp and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 74 Days and Sanofi SA for 94 Days on average.
| DUK | SNY | |
|---|---|---|
Market Cap | $91.10B | $95.18B |
Volume | 4,199,050 | 2,995,646 |
Sector | Utilities | Health |
52-Week High | $133.46 | $52.34 |
52-Week Low | $113.23 | $39.51 |
Typical Hold Time | 74 Days | 94 Days |
Enterprise Value | $183.61B | $114.48B |
Dividend Yield | 3.71% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $115.50, down 0.14% with a bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, 15.78% net income margin, and stable dividend payments. Recent news highlights Duke's positioning in data center growth opportunities while facing pressure from rising Treasury yields. The stock trades below analyst consensus target of $134.44 with 43.75% buy ratings.
DUK offers income investors a stable utility play with growth potential from data center demand, though rising interest rates and high debt levels present headwinds. The current valuation at 17.6 P/E appears reasonable given the company's consistent profitability and dividend reliability. Upside potential exists if data center contracts materialize as projected.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
